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ABSTRACT
Purpose: To assess the maximum-tolerated dose,
toxicity, and pharmacokinetics of DE-310, a macromole-
cular prodrug of the topoisomerase I inhibitor exatecan
(DX-8951f), in patients with advanced solid tumors.
Experimental Design: Patients received DE-310 as a
3-hour infusion once every 2 weeks (dose, 1.0-2.0 mg/m2)
or once every 6 weeks (dose, 6.0-9.0 mg/m2). Because
pharmacokinetics revealed a drug terminal half-life ex-
ceeding the 2 weeks administration interval, the protocol
was amended to a 6-week interval between administrations
also based on available information from a parallel trial
using an every 4 weeks schedule. Conjugated DX-8951 (the
carrier-linked molecule), and the metabolites DX-8951 and
glycyl-DX-8951 were assayed in various matrices up to 35
days post first and second dose.
Results: Twenty-seven patients were enrolled into the
study and received a total of 86 administrations. Neutropenia
and grade 3 thrombocytopenia, and grade 3 hepatotoxicity
with veno-occlusive disease, were dose-limiting toxicities.
Other hematologic and nonhematologic toxicities were mild
to moderate and reversible. The apparent half-life of
conjugated DX-8951, glycyl-DX-8951, and DX-8951 was
13 days. The area under the curve ratio for conjugated DX-
8951 to DX-8951 was 600. No drug concentration was
detectable in erythrocytes, skin, and saliva, although low
levels of glycyl-DX-8951 and DX-8951 were detectable in
tumor biopsies. One patient with metastatic adenocarcinoma
of unknown primary achieved a histologically proven
complete remission. One confirmed partial remission was
observed in a patient with metastatic pancreatic cancer and
disease stabilization was noted in 14 additional patients.
Conclusions: The recommended phase II dose of DE-
310 is 7.5 mg/m2 given once every 6 weeks. The active moiety
DX-8951 is released slowly from DE-310 and over an
extended period, achieving the desired prolonged exposure
to this topoisomerase I inhibitor.
INTRODUCTION
DE-310 is a novel macromolecular drug delivery system
for the topoisomerase I inhibitor DX-8951 (exatecan mesylate),
in which each molecule is linked via a glycyl-glycyl-phenyl-
alanyl-glycyl-peptidyl spacer to a biodegradable carboxyme-
thyldextran polyalcohol polymer. This carrier part of DE-310 is
intended to provide passive accumulation in tumor tissue and
sustained release of the active moiety DX-8951 within the
tumor, which occurs as result of enzymatic cleavage of the
peptidyl spacer by cathepsin B and cathepsin L, thereby
enhancing its activity and reducing its systemic toxicity (1).
The main chain is acid labile, suggesting that it is
biodegradable and can be depolymerized after endocytosis in
a lysosomal acidic-environment (Fig. 1; ref. 1).
The cytotoxicity of topoisomerase I inhibitors in animal
models increases with duration of exposure, and long-term
exposures to low concentrations are more effective than short-
term exposures to high concentrations (2). The concept behind
the development of DE-310 is that the macromolecular carrier
will accumulate and be retained preferentially in tumor tissue by
an enhanced permeability and retention effect (3–5).
Preclinical studies have revealed that the macromolecular
carrier is stable in plasma and is resistant to clearance by the
reticuloendothelial system. DE-310 showed antitumor activity
in various tumor models by single and repeated administration
(1), and antitumor activity was noted at lower doses than with
DX-8951. The two DE-310 breakdown products, DX-8951
and glycyl-DX-8951, were found to exert antitumor activity
in vivo (6), whereas the CYP3A4- and CYP1A2-mediated
DX-8951 metabolites referred to as UM-1 and UM-2 were
less potent (7–10).
Previous phase I clinical studies with various administration
schedules of DX-8951f have shown reversible, noncumulative,
and dose-dependent neutropenia and sometimes thrombocyto-
penia (11–16). Other side effects included mild to moderate
gastrointestinal toxicity (nausea, vomiting, stomatitis, and
diarrhea), fatigue, asthenia, and alopecia (11–16). Reversible,
noncumulative, neutropenia was the dose-limiting toxicity (DLT)
in all schedules (11–15), as well as transient and reversible liver
dysfunction (12, 14), or stomatitis in advanced leukemia (16).
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The objectives of this phase I study were (a) to determine
the maximum-tolerated dose and dose-limiting toxicities
(DLTs) of DE-310 when given i.v. once every 2 or 6 weeks,
(b) to characterize the pharmacokinetics of DE-310 (as
conjugated DX-8951) and its metabolites DX-8951 and
glycyl-DX-8951, and (c) to evaluate preliminary antitumor
activity.
PATIENTS AND METHODS
Eligibility Criteria. Patients with a histologically con-
firmed diagnosis of a malignant solid tumor refractory to
conventional chemotherapy or for whom no effective therapy
existed were eligible. Other eligibility criteria included the
following: age z 18 years; Eastern Cooperative Oncology Group
performance status 0 to 2; estimated life expectancy ofz8 weeks;
no previous anticancer therapy for at least 4 weeks (6 weeks for
nitrosoureas, mitomycin C, or carboplatin); and adequate
hematopoietic [absolute WBC count > 3,000/AL, absolute
neutrophil count > 1,500/AL, platelet count > 100  109/L,
and hemoglobin > 8.5 g/dL (or 5.2 mmol/L)], hepatic [serum
total bilirubin < 1.5 mg/dL (25.6 Amol/L), serum aspartate
transaminase, and alanine transaminase < 2.5 times the
institutional upper normal limit (<5.0 times upper normal limit
in case of liver metastases)], and renal (serum creatinine
concentration < 1.5 mg/dL or if raised between 1.5 and 2.0
mg/dL, then a creatinine clearance of >60 mL/min) function.
Specific exclusion criteria included symptomatic brain metasta-
ses, active or uncontrolled infection, known allergy to
camptothecin derivatives, concomitant treatment with CYP
3A4 inhibitors or inducers (wash-out period of at least 7 days
since last intake), or diarrhea (>2-3 stools/d above normal
frequency during the past 4 weeks). The institutional Ethical
Board approved the study protocol. All patients gave written
informed consent before study entry.
Treatment and Dose Escalation. DE-310 for injection
(37.9 mg of conjugated DX-8951 (i.e., equivalent to 2.5 mg of
DX-8951) and 165 mg maltose-monohydrate per 5 mL vial) was
provided as a lyophilized powder, and was stored in a
refrigerator at 2 to 8jC and protected from light in a closed
package. The drug was supplied by Daichii Pharmaceutical Co.,
Ltd. (Tokyo, Japan). DE-310 was reconstituted with 5 mL
of 0.9% sodium chloride to obtain a concentration of 0.5 mg
DX-8951 equivalent/mL solution and then filtered. The
appropriate volume of stock solution needed to yield the
required dose was diluted in a polyvinylchloride infusion bag
with 0.9% sodium chloride to 250 mL. This dilution was stable
for at least 24 hours when protected from light. The diluted drug
product was given protected from light over a period of 3 hours,
using a programmed peristaltic pump system. With the exception
of the first and second administration of the first and second
cycle of the q2w schedule and the first and second cycle of the
q6w schedule, respectively, in which patients were hospitalized
for pharmacokinetic blood sampling, patients were treated on an
outpatient basis. Prophylactic therapy was prohibited for the
first administration, but could be given from the second
Fig. 1 Schematic representa-
tion of intracellular drug release
by cleavage of the peptidyl
linker by lysosomal enzymes.
After internalization of the mac-
romolecular carrier DE-310
(MW, 3.4  105) by endocyto-
sis, the macromolecule is trans-
fe r red to the lysosomal
compartment, where it is ex-
posed to lysosomal enzymes
(i.e., cathepsin B and cathepsin
L). Both glycyl-DX-8951 and
free DX-8951 (MW, 435.48) are
liberated intracellularly. The
biodegradable polymer is me-
tabolized and afterwards excret-
ed renally.
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administration if treatment was delayed (>24 hours) or when
constant nausea and vomiting occurred. Prophylactic growth
factors were not allowed.
The starting dose of DE-310 was 1.0 mg/m2, and each
infusion was followed by a 2 weeks recovery period for every 28
days of treatment (q2w schedule) and was based on 1/6 of the
highest nonsevere toxic dose found in the dog. In the q2w
schedule, cycles were repeated every 28 days. After protocol
amendment to a six-weekly schedule, based upon available
information from a parallel phase I study using an every 4 weeks
schedule (17), the dose of DE 310 was escalated to 6.0 mg/m2,
followed by a 6-week interval (q6w schedule). Further dose
escalations were based on the prior dose level toxicity.
At least three patients were entered at each dose level. If
one of three patients experienced DLT, three additional patients
were to be entered at that dose level. The maximum-tolerated
dose was defined as one dose level below the dose that induced
DLTs in at least 2 out of 6 patients, defined as the National
Cancer Institute Common Toxicity Criteria version 2.0 grade 4
neutropenia lasting for z5 days, neutropenic fever (defined as
grade 4 neutropenia with fever z 38.5jC), thrombocytopenia
V25  109/L, any other clinically significant grade 4
hematologic toxicity, grade 3 or 4 vomiting despite maximum
supportive care, any other grade 3 or 4 nonhematologic
toxicity, and for the q2w schedule inability to start the second
administration of the first cycle or to start a second cycle after
a 1-week delay because of unresolved toxicity (18). Unresolved
toxicity was defined as WBC < 3.0  109/L, absolute
neutrophil count < 1.5  109/L, platelet count< 100  109/L,
and all associated nonhematologic toxicities (excluding
alopecia) not yet recovered to grade 0 to 1. Intrapatient
dose escalation was not allowed. The treatment was resumed
when the neutrophil count had recovered to z1.5  109/L,
the platelet count to z100  109/L, and any other treatment-
related toxicities were Vgrade 1.
Treatment Assessment. Before initiating therapy, a
complete medical history was taken and a physical examination
was done. A complete blood cell count and serum biochemistry
were done, as were ECG, urinalysis, and chest X-ray. Weekly
evaluations included history, physical examination, toxicity
assessment according to the National Cancer Institute Common
Toxicity Criteria, serum biochemistry, and urinalysis. Complete
blood cell counts were determined twice weekly throughout
every cycle. Tumor evaluation was done after every two cycles
in the q2w schedule, and after every cycle in the q6w schedule,
respectively, according to RECIST (19).
Sample Collection and Drug Analysis. For pharmaco-
kinetic analysis, a total of 40 blood samples (f6 mL each)
over a period of 8 weeks for the q2w schedule and over a
period of 12 weeks for the q6w schedule, respectively, was
obtained from an indwelling i.v. canula and collected into a
heparin-containing tube. In the q2w schedule, samples were
taken immediately prior to drug administration of DE-310, at
the end of infusion, and at 1, 2, 4, 6, 8, 24, 48, 96, and 144
hours post-end of infusion. In the q6w schedule, samples were
taken immediately prior to drug administration of DE-310, and
at 1, 2, 4, 6, 8, 24, 48, 72, 168, 240, 336, 504, 672, and 840
hours post-end of infusion. Blood specimens were immediately
put in an ice-water bath (4jC) until centrifugation at 2,000 rpm
for 15 minutes at 4jC. Plasma was transferred into plastic
specimen storage vials and stored frozen at 20jC until
analysis. Also, urine was collected for pharmacokinetic analysis
over a 24-hour period on days 1 to 8 in the first two cycles of
the q2w schedule and over a 24-hour period on days 1 to 2,
and over a 12-hour period on days 3, 7, 14, 21, 28, 35, and 42
in the first two cycles of the q6w schedule. Urine samples were
stored frozen at 20jC until analysis.
The plasma concentrations of conjugated DX-8951, glycyl-
DX-8951 and DX-8951 were quantified by a validated liquid
chromatographic method (MDS Pharma Services, Montreal,
Canada). Concentrations of conjugated DX-8951 were deter-
mined using a thermolysin enzymatic reaction and fluorescence
detection.
Samples of saliva and erythrocytes, normal skin, and
superficial tumor tissue, if possible, were obtained from patients
at the dose levels 6.0 and 7.5 mg/m2. Saliva was obtained during
the first cycle prior to drug administration, at the end of infusion,
4 hours post-end of infusion, and once a day on days 2, 3, 4, 8,
11, 15, 22, 29, and 36. Samples of erythrocytes were collected at
the time points indicated for plasma. The concentrations of
conjugated DX-8951, glycyl-DX-8951, and DX-8951 in saliva,
erythrocytes and ascites were quantified by a validated method
as described previously (20). Normal skin and tumor tissue was
obtained on day 8 or 9 of the first cycle and analyzed as
described for plasma (Shin-Nippon Biomedical Laboratory Ltd.,
Kainan, Japan).
Pharmacokinetic and Pharmacodynamic Data Analysis.
Pharmacokinetic variables were calculated by standard non-
compartmental methods using WinNonlin software version 3.3
(Pharsight, Mountain View, CA), and included time to peak
concentration (Tmax), peak concentration (Cmax), terminal half-
life (T1/2), and area under the curve (AUC). Urine excretion was
calculated in percentage of the dose given. Pharmacokinetic
variables are provided as mean values with the percent
coefficient of variation, and the level of significance (P) for
statistical tests was set at 0.05.
RESULTS
Patients and Treatment. A total of 27 patients (16
males and 11 females) with a median age of 57 years was
enrolled into the study between February 2001 and February
2003 (Table 1). All patients were eligible and assessable for
toxicity. A total of 61 cycles (i.e., 86 administrations) of
treatment was given at dose levels of 1.0 mg/m2 (q2w), 2.0
mg/m2 (q2w), 6.0 mg/m2 (q6w), 7.5 mg/m2 (q6w), and 9.0
mg/m2 (q6w). Twenty-five patients were assessable for
response; one patient died due to massive pulmonary
embolism before scheduled tumor reassessment, and another
patient withdrew because of rapid disease progression and was
replaced (i.e., dose level, 6.0 mg/m2).
Dose-Limiting Toxicity. At the starting dose of 1.0mg/m2,
the cohort was expanded to six patients because of the initial
classificationofDLTduetoprolongedgrade1thrombocytopenia in
one patient, delaying the second administration of DE-310 of the
first cycle. Mild thrombocytopenia, in retrospect, was related to
cirrhosis and esophageal varices resulting in occult gastrointestinal
bleeding. No further DLTs were observed with this schedule.
Because pharmacokinetics revealed a drug terminal half-life
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exceeding the 2 weeks administration interval, the protocol was
amended to a 6-week interval between administrations.
The initial three patients at the q6w schedule were treated at
a dose of 6.0 mg/m2 and experienced no DLTs. Subsequently, a
dose of 9.0 mg/m2 was explored, where two patients developed
DLT. A female patient with metastatic pancreatic cancer had
grade 4 leukocytopenia and grade 4 neutropenia with fever on
day 8, as well as grade 3 thrombocytopenia, grade 2 anemia, and
grade 3 hepatotoxicity (elevated transaminases). All side effects
were reversible. The second and third cycles were given at a
dose of 6.0 mg/m2 and were uneventful. A second female patient
with metastatic adenocarcinoma of unknown primary had an
uncomplicated first cycle, but on day 11 of her second cycle she
developed grade 3 thrombocytopenia, grade 3 neutropenia, grade
2 anemia, grade 3 hepatotoxicity (i.e., hyperbilirubinemia and
elevated transaminases). An ultrasound guided liver biopsy
revealed veno-occlusive liver disease (VOD). Hyperbilirubine-
mia persisted for 7 weeks and subsequently recovered but no
further DE-310 was given. In view of the DLTs observed at 9.0
mg/m2, the cohort of 6.0 mg/m2 was further expanded with three
additional patients, none of whom experienced DLTs. A total of
17 cycles were given at dose level 6.0 mg/m2.
Subsequently, an intermediate dose of 7.5 mg/m2 was
explored. At this dose level, a total of 10 cycles were given,
one out of six patients developed DLT consisting of grade 3
hepatotoxicity (i.e., hyperbilirubinemia and elevated trans-
aminases) occurring on day 15 of the second cycle. An
ultrasound guided liver biopsy again revealed VOD, which
was fully reversible within 15 weeks. The recommended dose
for phase II trials of DE-310 was set at 7.5 mg/m2 once every
6 weeks.
Hematologic and Nonhematologic Toxicity. A summary
of the worst grade hematologic toxicities per patient is
provided in Table 2. In addition to the dose-limiting toxicities,
the other observed nonhematologic toxicities were mild to
moderate and consisted of nausea, vomiting, stomatitis,
anorexia, asthenia, and alopecia (Table 3). Fifty-one percent
of patients experienced short lasting nausea, and 37%
experienced incidental vomiting. Prophylactic antiemetics were
not given. Reversible increase of the liver transaminases was
encountered in 12 out of 27 patients (44%) across all dose
levels, except 1.0 mg/m2 (Table 4).
Pharmacokinetics. Pharmacokinetic analysis was done
in all patients. Across the various dose levels, the apparent
terminal half-lives of conjugated DX-8951, glycyl-DX-8951,
and DX-8951 were 13, 12, and 13 days, respectively (Tables 5
and 6). Consequently, plasma concentrations of all compounds
conjugated were sustained for several weeks. This parallel
decline suggests that the terminal phase seen with the DE-310
metabolites (i.e., glycyl-DX-8951 and DX-8951) is not due to
real elimination processes but due to their much slower
formation from conjugated DX-8951. At the recommended
dose of 7.5 mg/m2, substantial interindividual variability was
observed (coefficient of variation, up to 92%). The AUC ratio
of conjugated DX-8951 to DX-8951 was f600, a similar
value seen as predicted by preclinical studies (1). The AUCs of
conjugated DX-8951, glycyl-DX-8951, and DX-8951 seemed
to increase in near proportion with an increase in dose.
Table 2 Hematological toxicity (worst grade per patient)
Anemia Leukocytopenia Neutropenia Thrombocytopenia
Grades
Dose (mg/m2) No. patients No. cycles No. administrations 1 2 1 2 3 4 1 2 3 4 1 2 3
Every 2 weeks
1.0 6 13 24 0 1 0 0 0 0 0 0 0 0 2 0 0
2.0 4 16 30 0 2 0 0 0 0 0 0 0 0 0 0 0
Every 6 weeks
6.0 7 17 17 1 2 2 0 0 0 2 0 0 0 1 0 0
7.5 6 10 10 2 3 0 1 0 0 0 0 1 0 0 1 1
9.0 4 5 5 0 2 2 1 0 1* 2 0 1 1* 0 0 2*
*Considered DLTs in two patients at dose level 9.0 mg/m2 every 6 weeks in the first and second cycle, respectively.
Table 1 Patient characteristics
Characteristic No. patients
No. patients
Total 27
Assessment
For dose-limiting toxicity 27
For efficacy 25
Gender, male to female 16:11
Age, y
Median 57
Range 31-78
ECOG performance status
0 7
1 19
2 1
Previous therapy
Chemotherapy only 19
Median no. regimens 2
Range 1-4
Radiotherapy 2
Both 3
None 3
Tumor types*
Gastrointestinal tract, including: 12
Colorectal cancer 6
Esophageal cancer 3
Pancreatic cancer 3
Melanoma 5
Lung cancer (NSCLC) 3
Soft tissue sarcoma 3
Unknown primary adenocarcinoma 2
Miscellaneous 4
Abbreviations: ECOG, Eastern Cooperative Oncology Group;
NSCLC, non–small cell lung carcinoma.
*Two patients had double tumors.
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Urinary excretion was very slow, and total drug recovery
over the entire sampling period amounted to <1%. In line with
the small distribution volume of conjugated DX-8951, concen-
trations of conjugated DX-8951, glycyl-DX-8951, and DX-8951
were not detectable in erythrocytes and saliva, further pointing to
limited distribution outside the plasma compartment. In tumor
biopsies of four patients, concentrations of both glycyl-DX-8951
and DX-8951 were detectable at low levels, whereas in normal
skin biopsies of nine patients concentrations of DX-8951
remained below the detection limit (Table 7). No drug levels
were obtained on the hepatic tissues of two patients taken at the
ultrasound guided liver biopsies.
During the first and second cycle at 6.0 mg/m2, the
concentrations were also assessed in ascites of a patient with
metastastic pancreatic cancer (Table 8).
Efficacy. A histologically proven complete remission,
confirmed by surgery and still persisting at a follow-up duration
of >2 years, was documented in the 56-year-old female with
lymph node metastases of adenocarcinoma of unknown primary,
who experienced DLT at dose level 9.0 mg/m2 and only received
two cycles.
A partial response lasting 3 months was achieved in a
46-year-old female with liver metastases from pancreatic
cancer initially treated at 9.0 mg/m2 during the first cycle
and treated at 6.0 mg/m2 during the second and third cycle.
Whereas according to actual measurements, another partial
remission of liver metastases was seen in a 58-year-old female
with metastatic ovarian cancer, treated at 2.0 mg/m2 for seven
cycles, we reassessed this response to stable disease since the
liver metastases were small and difficult to measure. The serum
levels of the tumor marker CA 125 in this patient has
decreased from 1,079 to 457 kilounits/L. Progression occurred
in this patient after 8 months. A total of 14 patients showed
disease stabilization for 6 weeks (n = 1, fibrous histiocytoma),
8 weeks (n = 1, colorectal cancer), 10 weeks (n = 1,
colorectal cancer), 12 weeks [n = 5, pancreatic cancer (n = 2);
colorectal cancer, adenocarcinoma of unknown primary, and
melanoma (each n = 1)], 16 weeks (n = 1, urothelial cancer),
18 weeks (n = 2, non–small cell lung carcinoma and
leiomyosarcoma uteri), 24 weeks (n = 2, colorectal cancer and
alveolar soft part sarcoma), and 32 weeks (n = 1, ovarian
cancer).
DISCUSSION
We did this study to assess the safety, tolerability,
maximum-tolerated dose, and pharmacokinetics of DE-310, a
macromolecular prodrug of the topoisomerase I inhibitor
exatecan (DX-8951f), given as a 3-hour i.v. infusion once every
2 or 6 weeks.
The present study showed that prolonged concentrations of
DX-8951 were achieved by only single short infusion of DE-310
given every 6 weeks, which confirmed the pharmacokinetic
proof of principle yielding the extended exposure to the
topoisomerase I inhibiting active moiety.
Because of the long half-life, which approximated a 2-week
administration interval and largely exceeded the half-life
expected based on preclinical data, further exploration of the
q2w schedule was considered illogical in view of the potential
for drug accumulation, and therefore the study protocol was
Table 3 Nonhematological toxicity (worst grade per patient)
Nausea Vomiting Stomatitis Anorexia Fatigue Alopecia
Grades
Dose (mg/m2) No. patients No. cycles No. administrations 1 2 1 2 1 2 1 2 1 2 1 2
Every 2 weeks
1.0 6 13 24 1 0 1 0 0 0 0 0 2 1 0 0
2.0 4 16 30 2 1 2 1 0 0 0 0 1 2 1 0
Every 6 weeks
6.0 7 17 17 5 0 0 3 2 1 3 1 5 2 1 0
7.5 6 10 10 2 1 0 1 1 0 3 0 6 0 1 0
9.0 4 5 5 2 0 2 0 0 0 1 0 2 1 1 0
Table 4 Hepatotoxicity (worst grade per patient)
ALT AST Total bilirubin
Grades
Dose (mg/m2) No. patients No. cycles No. administrations 1 2 3 1 2 3 1 2 3
Every 2 weeks
1.0 6 13 24 0 0 0 0 0 0 0 0 0
2.0 4 16 30 0 1 0 1 1 0 1 0 0
Every 6 weeks
6.0 7 17 17 2 0 0 4 0 0 0 0 0
7.5 6 10 10 0 2 1* 0 1 2* 1 1 1*
9.0 4 5 5 1 0 2y 1 1 2y 0 0 1*
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.
*Considered a DLT in one patient at dose level 7.5 mg/m2 every 6 weeks, and in one patient at dose level 9.0 mg/m2 every 6 weeks in the second cycle.
yConsidered a DLT in one patient at dose level 9.0 mg/m2 every 6 weeks in the first cycle.
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amended to a 6 weeks schedule based on available information
from a parallel trial using an every 4 weeks schedule (17). The
pharmacokinetics showed near dose proportionality of conju-
gated DX-8951, glycyl-DX-8951, and DX-8951.
Reversible grade 4 myelosuppression and grade 3
hepatotoxicity with VOD were the principal DLTs and were
observed at dose levels 9.0 mg/m2 (2 out of 4 patients) and 7.5
mg/m2 (1 out of 6 patients), respectively. It is of interest to
Table 6 Mean (CV%) pharmacokinetic parameters of conjugated DX-8951, glycyl-DX-8951, and DX-8951 of second administration at first course in
every 2-week schedule and at second course in every 6-week schedule
Conjugated DX-8951 Glycyl-DX-8951 DX-8951
Dose
(mg/m2)
AUC0-t
(ng h/mL)
AUC0-336 h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
AUC0-t
(ng h/mL)
AUC0-336 h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
AUC0-t
(ng h/mL)
AUC0-336h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
Every 2 weeks
1.0 Mean 31,256.5 n/a 324.9 3.8 n/a 321.7 n/a 3.8 36.5 n/a 321.8 n/a 4.9 51.0 n/a
(n = 4) CV% 114.8 72.9 25.5 111.5 134.4 116.3 66.7 98.5 66.6
2.0 Mean 221,846.0 n/a 1,230.3 3.5 n/a 834.5* n/a 4.0* 292* n/a 631.0* n/a 3.1* 326* n/a
(n = 4) CV% 75.1 42.8 16.5 93.9 112.7 143.1 86.2 115.7 119.9
Every 6 weeks
6.0 Mean 750,514.6 519,098.0 3,541.4 6.0 295.8 2,989.8 1,540.0 7.5 n/a n/a n/a n/a n/a n/a n/a
(n = 5) CV% 32.6 25.6 22.0 47.1 19.7 100.4 72.4 98.4 n/a n/a n/a n/a n/a n/a n/a
7.5 Mean 1,180,980.0 813,841.0 5,081.0 6.3 418.3 1,3080.3 6,324.2 33.4 n/a n/a n/a n/a n/a n/a n/a
(n = 3) CV% 42.7 39.0 13.2 63.8 38.2 102.8 98.0 110.9 n/a n/a n/a n/a n/a n/a n/a
9.0 Mean 1,313,751.0 920,467.3 4,868.5 15.0 267.0 13,893z 3,814.9z 36.5z 339z 616z 7039.3z 2811.5z 19.8z 339z 181z
(n = 2)yCV% 71.7 73.8 55.7 113.1 4.2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
NOTE. AUC0-t : AUC calculated from time 0 to the last nonzero concentration; AUC0-336 h: AUC calculated from time 0 to the concentration at
time 336 hours post-end of infusion, where possible. Because the distribution phase of glycyl-DX-8951 and DX-8951f from conjugated DX-8951 and
the glycyl-DX-8951 and DX-8951 elimination phase could be simultaneously occurring over the dosing interval, a true terminal elimination phase
cannot be accurately characterized using noncompartimental methods. An apparent elimination phase half-life (T1/2,app.) is therefore reported here.
Abbreviations: CV, coefficient of variation; Cmax, peak plasma concentration; Tmax, time to Cmax; T1/2, half-life of terminal phase; n/a, not available.
*Calculated on data from three patients.
yDose reduction from 9.0 to 6.0 mg/m2 (every 6 weeks) for one patient in course 2.
zCalculated on data from one patient.
Table 5 Mean (CV%) pharmacokinetic parameters of conjugated DX-8951, glycyl-DX-8951, and DX-8951 of first administration at first course in
every 2-week schedule and at first course in every 6-week schedule
Conjugated DX-8951 Glycyl-DX-8951 DX-8951
Dose
(mg/m2)
AUC0-t
(ng h/mL)
AUC0-336 h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
AUC0-t
(ng h/mL)
AUC0-336 h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
AUC0-t
(ng h/mL)
AUC0-336 h
(ng h/mL)
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
Every 2 weeks
1.0
(n = 6)
Mean 38,402.0* n/a 460.8 5.3 n/a 238.5 n/a 1.54 132.0 n/a 158.6 n/a 0.87 135.0 n/a
CV% 67.7 53.8 47.6 67.8 71.7 51.9 72.5 71.7 44.6
2.0
(n = 4)
Mean 61104.0y n/a 582.6y 4.0y n/a 515.8z n/a 2.23y 99.0* n/a 366.6z n/a 1.6 87.0 n/a
CV% n/a n/a n/a 130.2 123.7 39.6 111.7 100.7 52.8
Every 6 weeks
6.0
(n = 7)
Mean 661,924.4 498,855x 3,344.7 5.0 243.4 1,731.2 929.2x 6.71 251.0 348.4 960.4 642.8x 3.2 150.4 260.8
CV% 45.5 36.0 17.5 38.3 40.8 55.5 60.0 93.3 78.9 47.0 39.2 34.7 56.6 50.8 21.1
7.5
(n = 6)
Mean 1,124,472.3 793,120.2 5,706.3 4.7 338.8 3,907.2 2,492.4 11.6 123.0 330.2 1781.1 1168.1 5.2 151.0 302.0
CV% 19.4 20.1 18.9 50.1 18.3 90.1 92.6 93.7 42.7 78.5 78.9 83.6 84.5 68.5 54.0
9.0
(n = 4)
Mean 902,743.5 629,527.3 4,218.9 5.5 309.5 3,178.7 2,299.6 12.6 183.0 186.3 2062.8 1479.0 6.9 135.0 169.5
CV% 60.3 56.5 33.8 54.5 37.3 71.5 89.9 118.0 71.4 16.2 53.2 56.3 66.8 65.7 18.4
NOTE. AUC0-t : AUC calculated from time 0 to the last nonzero concentration; AUC0-336h: AUC calculated from time 0 to the concentration at time
336 hours post-end of infusion, where possible. Because the distribution phase of glycyl-DX-8951 and DX-8951f from conjugated DX-8951 and the
glycyl-DX-8951 and DX-8951 elimination phase could be simultaneously occurring over the dosing interval, a true terminal elimination phase cannot be
accurately characterized using noncompartimental methods. An apparent elimination phase half-life (T1/2,app.) is therefore reported here.
Abbreviations: CV, coefficient of variation; Cmax, peak plasma concentration; Tmax, time to Cmax; T1/2, half-life of terminal phase; n/a, not available.
*Calculated on data from four patients.
yCalculated on data from one patient.
zCalculated data from three patients.
xCalculated on data from six patients.
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note that the AUCs of conjugated DX-8951, glycyl-DX-8951,
and DX-8951 were 10-fold higher in the second cycle of the
two patients with resulting VOD compared with the other
patients at the same dose levels. The reason for this large
interpatient variation in pharmacokinetics remains to be
elucidated. The recommended dose for phase II studies is
7.5 mg/m2 once every 6 weeks. At this dose and schedule,
circulating concentration of the active moiety DX-8951 after a
single infusion of DE-310 were similar to those achieved at
the maximum-tolerated dose of a 21-day continuous infusion
of DX-8951f at 0.15 mg per m2 per day (Fig. 2; ref. 21). The
number of patients with multiple courses is limited in this
study. Thus, we can not fully exclude the possibility of
toxicity being cumulative and therefore also a longer cycle
interval or a lower dose of 6 mg/m2 every 6 weeks may be
considered for future studies. Because we were unable to
study this, it can not yet be completely excluded that the
polymer accumulates in the liver and thereby generates liver
damage.
Other nonhematalogic toxicities attributed to the treatment
of DE-310 included mild to moderate nausea, vomiting,
stomatitis, anorexia, asthenia, and alopecia, a toxicity profile
similar to that of single agent exatecan mesylate (DX-8951f;
refs. 11–15).
The observed myelosuppression was an expected side
effect, known to be a class effect of topoisomerase I
inhibitors. The nadirs of absolute neutrophil count and
platelets were reached at 22 days (range, 18-29 for absolute
neutrophil count and 11-36 for platelets) post-infusion.
Myelosuppression was always fully reversible after a median
of 14 days (range, 3-23) post-nadir. In view of the presence of
circulating active drug moiety at the time of nadir and the
conceptual likelihood that colony-stimulating growth factors
could thus actually increase severity and duration of
myelosuppression by stimulating stem cells, whereas exposed
to cytotoxics, the administration of agents like granulocyte
colony-stimulating factor was specifically avoided.
The other DLT was hepatotoxicity consisting of reversible
increases in liver transaminases and bilirubin, and in two
patients correlated with presence of hepatic VOD. Hepatic
VOD results from toxic injuries to the hepatic sinusoids (zone
3 of the liver acinus), followed by a series of biological
processes that lead to circulatory compromise of centrilobular
hepatocytes, fibrosis, and obstruction of liver blood flow
Table 7 Concentrations (ng/g) of DE-310 (as conjugated DX-8951), G-DX-8951 and DX-8951 in normal skin tissues (normal) and tumor biopsies
(tumor)
Patient
(tumor type)
Dose,*
(mg/m2)
Time of biopsy at
first cycle (d)
Normal versus
tumor
Biopsy of tumor
type
Weight of
sample (mg)
Conjugated
DX-8951
G-DX-8951 DX-8951
19 (sarcoma) 6.0 8 Normal 5.8 BLQ BLQ BLQ
20 (colorectal) 6.0 8 Normal 9.8 BLQ 62.731 BLQ
21 (melanoma) 6.0 9 Normal 32.7 BLQ 24.524 BLQ
Tumor Melanoma 153.5 166.159 134.457 8.037
22 (melanoma) 7.5 9 Normal 18.9 BLQ 53.448 BLQ
Tumor Melanoma 2,294.1 303.557 155.276 4.188
23 (melanoma) 7.5 8 Normal 15.9 BLQ 59.173 BLQ
Tumor Melanoma 2,223.0 222.019 119.103 4.157
24 (NSCLC) 7.5 8 Normal 9.3 BLQ 10.870 BLQ
25 (ACUP) 7.5 9 Normal 9.2 BLQ 5.617 BLQ
26 (sarcoma) 7.5 8 Normal 27.2 BLQ 8.419 BLQ
9 Tumor Sarcoma 414.2 160.690 54.202 2.159
27 (melanoma) 7.5 8 Normal 29.1 BLQ 10.199 6.613
Abbreviations: G-DX-8951, glycyl-DX-8951; BLQ, below limit of quantitation; NSCLC, non–small cell lung cancer; ACUP, adenocarcinoma
unknown primary.
*Every 6 weeks.
Table 8 Concentrations (ng/mL) of DE-310 (as conjugated DX-8951), G-DX-8951, and DX-8951 in plasma and ascites in one patient with metastatic
pancreatic cancer (dose, 6.0 mg/m2, every 6 weeks)
Plasma Ascites
Cycle Day Conjugated DX-8951 G-DX-8951 DX-8951 Conjugated DX-8951 G-DX-8951 DX-8951
1 1 2,987.9* 2.333y 0.545y nd nd nd
15 424.3 1.974 0.448 1,401.97 3.66 0.61
29 119.3 0.610 0.149 382.18 0.46 0.11
36 BLQ 0.352 0.084 232.82 BLQ BLQ
39 nd nd nd 197.51 BLQ BLQ
2 1 4,067.1z 2.643y 0.785y 172.49 BLQ BLQ
4 1,759.9 7.912 1.578 3,164.66 6.74 0.67
18 nd nd nd 572.32 1.64 0.21
22 305.9 0.948 0.181 466.62 1.10 0.18
30 BLQ 0.321 0.073 103.1 BLQ BLQ
Abbreviations: G-DX-8951, glycyl-DX-8951; nd, not determined; BLQ, below limit of quantitation (for ascites <0.5 ng/mL).
*Maximum concentration at 4 hours after end of infusion.
yMaximum concentration at 24 hours after end of infusion.
zMaximum concentration at 2 hours after end of infusion.
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(22, 23). Histology showed diffuse damage in the centrilobular
zone of the liver, in combination with sinusoidal fibrosis,
necrosis of pericentral hepatocytes, narrowing, and fibrosis of
central veins. Although drug-induced VOD is most frequently
observed following stem cell transplantations with high-dose
busulfan and cyclofosfamide, it can occur after various
regimens of chemotherapy at conventional doses (e.g.,
actinomycin D, dacarbazine, cytosine arabinoside, mitramycin,
and 6-thioguanine), combination chemotherapy, or (total body)
irradiation. It has been suggested that drugs or toxins can
induce depletion of glutathione leading to cell death and
yielding increased activity of matrix metalloproteinases,
resulting in degradation of the extracellular matrix and loss
of sinusoidal endothelial cells from the space of Disse (22, 23).
Hepatotoxicity was also reported in a phase I study of N-
(2-hydroxypropyl)-methacrylamide copolymer conjugates of
doxorubicine (24) but not for MAG-camptothecin (25), and the
phase I study of pegylated camptothecin (26). It therefore
remains unclear if the carrier is responsible for this phenomenon,
or whether both carrier and active drug are responsible. Whereas
VOD is a severe side effect, the fact that even the most severe
cases of hepatotoxicity in our trial showed full reversibility
indicates that with proper monitoring the drug DE-310 can be
safely used at the recommended dose of 7.5 mg/m2 every 6
weeks.
Concentrations of conjugated DX-8951, glycyl-DX-8951,
and DX-8951 were determined in ascites samples in a patient
with advanced pancreatic disease treated at dose level
6.0 mg/m2. These data indicated significant exposure of the
peritoneal cavity to conjugated DX-8951, glycyl-DX-8951,
and DX-8951 at concentrations exceeding those in simulta-
neously obtained plasma samples.
The results of studies assessing DE-310, glycyl-DX-8951,
and DX-8951 in normal skin, erythrocytes, and saliva would seem
to fit with the long circulation times combined with the formation
rate-limited elimination and the hypothesis of preferential drug
uptake by tumor tissue and not in other tissues. However, the
sample size and available data are too limited to draw definitive
conclusions. Notwithstanding, it can be concluded that the
biodistribution of this polymerized agent is substantially different
from that of the registered topoisomerase I inhibitors topotecan
(27) and irinotecan and its metabolite SN-38 (28).
In summary, by employing a polyalcohol carrier with
cleavable linking peptide as a drug delivery system, the
pharmacokinetics profile of topoisomerase I inhibitor DX-
8951f seems to be improved, providing slow release of the
active moiety over a very extended period. This together with the
presence of discernable drug levels in tumor and the below limits
of quantification drug levels in normal tissues provides
supportive evidence to the validity of the concept of using
macromolecular carriers to enhance the potential efficacy and
diminish the toxicity of topoisomerase I inhibitors and warrants
further evaluation in phase II studies.
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